News

With an orphan drug status for the treatment of acute myeloid leukemia (AML), the novel targeted therapy is directed to the interleukin-3 receptor (IL-3R) present on tumor bulk

In exchange, BioLineRx will receive an upfront license fee, along with future development, regulatory and commercialisation milestones together worth approximately $30m in addition to projected sales-based royalties. CTTQ

As the first and only four-strain influenza vaccine option for patients as young as six months of age, Fluzone Quadrivalent vaccine is the newest addition to the Fluzone

iMed will leverage IT solutions to share and manage complex data with clinical trial investigators and other external partners on a common portal. AZ NS iMed vice president

Expected to be set up within a year, the new pharmaceutical technology centre will focus on drug discovery, process development and commercialization, drug characterization, drug delivery and diagnostics.

Covering areas like physical sciences, medical research, advanced materials, pharmaceutical manufacturing and advanced manufacturing, the projects focus on challenges such as developing new treatments for cancer and ensuring

Besides collaborating on three cancer targets, AstraZeneca is also developing two antisense drugs, ISIS-AR and ISIS-STAT3 discovered by Isis. AstraZeneca had acquired license for the two antisense drugs

Packaging of the bottle does not comply with the requirements of the Poison Prevention Packaging Act. The dietary supplement bottles contain 90 tablets of 25mg iron supplement each,

As per the definitive agreement signed between both the parties, AstraZeneca will acquire Pearl’s shares for initial consideration of $560m that is payable on completion of the transaction.